German vaccine panel endorses Astra-Sanofi's RSV shot for infants
FRANKFURT, June 27 (Reuters) -Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca AZN.L and Sanofi's SASY.PA antibody therapy to protect them against the common respiratory infection RSV.
The recommendation regardless of risk factors is another boost for the product, which has seen strong U.S. demand well above supplies during the first winter there.
The panel of independent experts known as STIKO is widely followed by family doctors in Germany, Europe's largest pharmaceutical market.
A study by U.S. public health agency CDC showed in March that Beyfortus, part of a category known as passive immunisation, was 90% effective in protecting infants from RSV related hospitalizations.
The therapy won approval in Europe to protect infants in November 2022 and in the United States in July 2023.
STIKO added it would need more data before it could issue a view on Pfizer's PFE.N rival RSV vaccine Abrysvo, which is given to pregnant women to protect their babies.
The use of Beyfortus in the elderly would also require further assessment, it said.
Reporting by Patricia Weiss
Writing by Ludwig Burger
Editing by Madeline Chambers
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
